News Releases

Date Title and Summary
Toggle Summary electroCore to Announce Second Quarter Financial Results on Wednesday, August 9
ROCKAWAY, N.J. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August
Toggle Summary electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
ROCKAWAY, N.J. , July 31, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate
Toggle Summary gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)
ROCKAWAY, N.J. , July 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript,  Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working
Toggle Summary electroCore Expands Intellectual Patent Portfolio for nVNS Technology
ROCKAWAY, N.J. , July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile
Toggle Summary electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
ROCKAWAY, N.J. , July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Reletex TM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea
Toggle Summary electroCore Provides Select Second Quarter 2023 Financial Guidance
Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 ROCKAWAY, N.J. , July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
Toggle Summary gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
ROCKAWAY, N.J. , July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids
Toggle Summary TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project
ROCKAWAY, N.J. , June 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air
Toggle Summary electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC
ROCKAWAY, N.J. , June 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted
Toggle Summary electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
ROCKAWAY, N.J. , June 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65 th Annual